Impact of lung biomarker testing on out-of-pocket costs for metastatic non-small cell lung cancer.

11087 Background: Biomarker testing in metastatic non-small lung cancer (NSCLC) is critical for appropriate selection of therapy options. Claims-based datasets offer real-world information on the use and cost of biomarker testing across the United States. Methods: We used de-identified administrative claims data from Optum’s Clinformatics Data Mart Database (CDM) from 2013 to 2021 to assess for trends in biomarker testing. Eligible patients were adults with two or more lung cancer diagnosis codes and with two or more claims of a secondary malignant neoplasm. Patients were excluded if they had another primary cancer or did not have continuous insurance coverage twelve months prior and six months after diagnosis. We assessed claims-based out-of-pocket (OOP) costs associated with testing and treatment. Descriptive statistics were used to assess biomarker testing rates, and multivariable analyses (MVA) were performed to assess factors associated with testing. Results: A total of 4377 patients with metastatic NSCLC were eligible (mean age 60 years (SD: 8. 33 years), 49. 6% female, 76. 7% former smokers). Testing rates within two months of diagnosis increased from 58. 15% in 2013 to 69. 96% in 2021. On MVA, biomarker testing was associated with younger age, being non-smokers, living in Mountain geographic region, or having point-of-service insurance plans. Biomarker testing was associated with a median OOP cost of 98 (IQR: 43. 87-306. 58). Patients who underwent biomarker testing had a median total OOP cost of all services within 6 months of diagnosis of 3560. 20 (IQR: 1538. 37-6199. 44) compared to 1979. 58 (IQR: 725. 75-4003. 06) for those who did not undergo biomarker testing. Conclusions: Using claims data, we find that 70% of patients with metastatic NSCLC undergo biomarker testing within two months of diagnosis with metastatic disease. Most patients undergo biomarker testing early in their treatment course (0-60 days), suggesting that testing is appropriately being obtained early on in their treatment course, but this testing is associated with substantially higher overall OOP costs to patients.